In vitro humanized 3D microfluidic chip for testing personalized immunotherapeutics for head and neck cancer patients.

CONCLUSION: We introduced the first humanized in vitro microfluidic chip assay to test immunotherapeutic drugs against HNSCC patient samples. This assay could be used to predict the efficacy of immunotherapeutic drugs for individual patients.
PMID: 31356815 [PubMed - as supplied by publisher]

Source: Experimental Cell Research - July 25, 2019 Category: Cytology Authors: Al-Samadi A, Poor B, Tuomainen K, Liu V, Hyytiäinen A, Sulymanova I, Mesimaki K, Wilkman T, Mäkitie A, Saavalainen P, Salo T Tags: Exp Cell Res Source Type: research